美通社

2024-09-10 08:00

Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces an oral presentation of updated results from a pivotal Phase 2 clinical trial of Dupert®(fulzerasib)for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation at the 2024 World Conference on Lung Cancer (WCLC).

Fulzerasib is a novel, orally active, potent KRAS G12C inhibitor. Based on the results from this single-arm registrational Phase 2 clinical study (NCT05005234).

Dupert® (fulzerasib) received approval by the NMPA in August 2024 for the treatment of adult patients with advanced NSCLC harboring the KRAS G12C mutation who have received at least one systemic therapy.

As of the data cutoff date (Dec 13, 2023), a total of 116 NSCLC subjects were enrolled and evaluable.

  • Fulzerasib showed encouraging antitumor activity. The confirmed objective response rate (ORR) assessed by the Independent Radiology Review Committee (IRRC) was 49.1% (95% CI: 39.7-58.6). The disease control rate (DCR) was 90.5% (95%CI: 83.7, 95.2). The median duration of response (DoR) has not yet been reached, while the median progression-free survival (PFS) was 9.7 months (95%CI: 5.6-11.0). Median overall survival (OS) has not been reached.
  • Fulzerasib was generally well-tolerated, with no additional safety signals observed. Treatment-related adverse events (TRAEs) occurred in 92.2% of patients (107 individuals), mostly Grade 1-2. The most common TRAEs included anemia, increased alanine aminotransferase, increased aspartate aminotransferase, asthenia and proteinuria.

Professor Yi-Long Wu from Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, stated: "As a potent KRAS G12C inhibitor, Dupert® monotherapy has demonstrated encouraging efficacy in advanced lung cancer with KRAS G12C mutations, with the pivotal registry study meeting the prespecified primary endpoints and overall favorable safety profile. As the first KRAS G12C inhibitor approved in China, Dupert® provides a new treatment option for cancer patients harboring this gene mutation in China. We look forward to seeing more KRAS G12C-mutated patients with advanced lung cancer benefit from this drug soon."

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are pleased to share the latest clinical data from the registration study of Dupert® at the WCLC. Thanks to the exceptional efficacy and good tolerability demonstrated in this study, Dupert® was recently approved as the first KRAS G12C inhibitor in China. Moving forward, we remain committed to advancing Dupert® as both a monotherapy and in combination treatments, aiming to maximize the clinical value of this innovative targeted drug and benefit more patients."

About Dupert® (Fulzerasib, KRAS G12C Inhibitor)

The RAS protein family is categorized into KRAS, HRAS and NRAS categories. KRAS mutation are detected in nearly 90% of pancreatic cancers, 30-40% of colon cancers, and 15-20% lung cancers. The KRAS G12C mutation is more prevalent than the combined occurrence of ALK, ROS1, RET and NTRK 1/2/3 mutations.

Fulzerasib is a novel, orally active and potent KRAS G12C inhibitor designed to effectively target the GTP/GDP exchange—an essential step in pathway activation—by covalently and irreversibly modifying the cysteine residue of KRAS G12C protein. Preclinical cysteine selectivity studies demonstrated high selectivity of fulzerasib towards G12C, leading to inhibition of downstream signaling, resulting in tumor cells apoptosis and cell cycle arrest.

In September 2021, Innovent and GenFleet Therapeutics entered an exclusive license agreement for the development and commercialization of fulzerasib (Innovent R&D code: IBI351, GenFleet R&D code: GFH925) in China, including mainland China, Hong Kong, Macau and Taiwan.

In January 2023, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation (BTD) to fulzerasib for the treatment of patients with advanced NSCLC harboring KRAS G12C mutation who have received at least one prior systemic therapy. In May 2023, another BTD was granted for the treatment of advanced CRC patients with KRAS G12C mutation who had undergone at least two systemic therapies.

As of August 2024, the CDE of NMPA has approved fulzerasib for the treatment of adult patients with advanced NSCLC harboring the KRAS G12C mutation who have received at least one systemic therapy.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 11 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. 

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

source: Innovent Biologics

《說說心理話》成人亦會專注力不足?嘉賓分享中年確診過度活躍症+自閉症過程!► 即睇

人氣文章
最近7天
沒有相關資料。
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
3
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
6
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
7
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
8
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
9
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
10
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
11
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
12
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
13
阿里 | 推新AI模型聲稱超越DeepSeek,股價逆市飆逾半成仍有上升空間?
14
【FOCUS】關稅孤注一擲,Trumponomics欲留青史
15
法國總統馬克龍晤鄭志剛,研23萬億元文化產業機會
16
港股 | 蕭猷華:恒指短線回調,中線繼續看好
17
中芯 | 傳晶片技術出現突破,股價連日飆升創新高可以點部署?
18
iPhone SE 4或於本周內上架官網
19
高息定存 | 信銀國際12個月港元定存高達3.5厘
20
David Webb:因病情惡化,將有序結束個人財經網站
21
AI | DeepSeek日活躍用戶達二千萬,據報在港設兩公司
22
神州經脈 | 多國限制用DeepSeek,美郵政恢復收中港包裹
23
大摩:29隻內地股票存重大關稅風險,重申謹慎看法
24
貿易戰 |【FOCUS】侵侵扼殺「小額豁免」,雙刃劍效應衝擊大
25
馬斯克 | 【FOCUS】DOGE掀精簡風暴,「全能者」上身影響難料
26
關稅戰 | 觸發避險金價屢創新高看3000美元,應揀買金礦股抑或黃金ETF?
27
預算前瞻 | 稅務學會:非開徵消費稅合適時機,倡外地藝員及運動員稅率扣減
28
大腸桿菌 | 瑪嘉烈醫院3醫生疑感染產志賀毒素一人死,推斷或進食受污染食物
29
貿易戰 | 特朗普計劃周一宣布,對鋼、鋁進口加徵25%關稅
30
中概股 | 大鱷撈底王泰珀增持中概股 專家稱可跟投資惟要承受較大風險
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老